CurrentCignaPolicy IP0271

Iron Chelators (Oral)

Cigna coverage policy for oral iron chelators (Exjade/Jadenu [deferasirox] and Ferriprox [deferiprone], including generics and formulations) specifying medical necessity criteria, preferred product/step requirements by plan type, approval durations, exclusions, and applicable formulary substitution rules.

Policy Summary

PayerCigna

PolicyIron Chelators (Oral)

Policy CodePolicy IP0271

Change TypeAnnual revisions (2024, 2025) - criteria & preferred product updates

Effective DateMay 1, 2025

Next Review Date

Key ActionDocument required serum ferritin thresholds and hematology consultation for initiation and follow plan-specific preferred product/prior authorization requirements.

SourceLink

POLICY UPDATE CHANGES

Removed age from Deferasirox indications for Iron Overload, Chronic - Transfusion-Related and Non-Transfusion-Dependent Thalassemia Syndromes.

Removed requirement for Liver Iron Concentration (LIC ≥ 5 mg Fe/g dry weight) from Deferasirox non-transfusion-dependent thalassemia criteria.

Updated verbiage for 'Patients Currently Receiving an Oral Chelator' approval to 'Approve if the patient is benefiting from therapy, according to the prescriber.'

Updated preferred product criteria for Ferriprox 1000 mg (twice daily) and Ferriprox 500 mg/1000 mg (three times daily) formulations.

2Primary active ingredients covered

1 year

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Approval duration when criteria met

>=300/>=1000Key serum ferritin thresholds (mcg/L)

Coverage Summary & Stance

Coverage stance: covered_with_criteria. Scope: Cigna covers oral iron chelators deferasirox (Exjade, Jadenu, generics — tablets for suspension, tablets, granules) and deferiprone (Ferriprox, generics — tablets and oral solution) for labeled indications when medical necessity criteria are met. Plan lines and formulary rules apply (preferred product/step requirements and plan-specific prior authorization may be required).

Key exclusions/high-level limits: uses not supported by the policy are considered experimental, investigational, or unproven and are not covered until criteria are updated. Deferasirox and deferiprone are limited to the FDA‑approved transfusion-related and certain non‑transfusion‑dependent thalassemia indications per the policy.

Reference thresholds and approval duration: initial transfusion‑related therapy requires pre‑treatment serum ferritin > 1,000 mcg/L; non‑transfusion‑dependent thalassemia initial therapy requires serum ferritin > 300 mcg/L. When criteria are met, approvals are for 1 year.

Medical Necessity Criteria — Deferasirox (Exjade, Jadenu, generics)

Medical Necessity Criteria — Deferiprone (Ferriprox, generics)

Preferred Product / Step Therapy Requirements (by Plan)

Employer / Individual & Family Plans - Preferred Product / Step Criteria

Plan-specific product substitution or trial requirements for covered formulations

ALL of the following

Exjade (deferasirox tablet for suspension) criteria: Criteria = Trial of deferasirox tablet for suspension (the bioequivalent generic product) AND cannot take due to a formulation difference in the inactive ingredient(s) which would result in a significant allergy or serious adverse reaction.
Applicable to Employer and Individual & Family Plans per plan tables.
Jadenu (deferasirox tablet) criteria: Criteria = Trial of deferasirox tablet (the bioequivalent generic product) AND cannot take due to a formulation difference in the inactive ingredient(s) which would result in a significant allergy or serious adverse reaction.
Applicable to Employer and Individual & Family Plans per plan tables.
Jadenu Sprinkle (deferasirox oral granules) criteria: Criteria = Trial of deferasirox granule packet (the bioequivalent generic product) AND cannot take due to a formulation difference in the inactive ingredient(s) which would result in a significant allergy or serious adverse reaction.
Applicable to Employer and Individual & Family Plans per plan tables.

The policy defines Preferred product criteria as plan‑specific requirements to trial a bioequivalent generic product or demonstrate intolerance/allergy to inactive ingredients before alternate formulations are approved.

Plan applicability: the Employer and Individual & Family Plans include specific preferred product/step criteria for formulations; notably, Ferriprox oral solution (deferiprone) criteria are specified for Employer and Individual & Family Plans and may require prior authorization.

Policy revisions: changes expanded the Ferriprox oral solution criteria to add the options 'Dose prescribed cannot be attained with deferiprone tablets' and 'patient cannot swallow or has difficulty swallowing tablets' (Annual Revision 5/1/2024). The 5/1/2025 revision also updated preferred product criteria for Ferriprox 1000 mg and 500/1000 mg formulations and removed some prior product criteria for Individual & Family Plans.

Provider Actions & Documentation Requirements

Prior Authorization

Prior authorization may be required

Certain products and plan lines may require prior authorization per plan-specific preferred product criteria (e.g., trials of generic bioequivalent formulation or inability to tolerate inactive ingredients); Employer and Individual & Family Plans note '[may require prior authorization]'.

Employer
Individual & Family Plans
Preferred product trials of bioequivalent generic formulations (e.g., deferasirox tablet for suspension/tablet/granules; deferiprone tablets)

Documentation Required

Laboratory documentation required for initiation

For initial therapy, provider must document prior serum ferritin level > 1,000 mcg/L for transfusion-related iron overload or > 300 mcg/L for non-transfusion-dependent thalassemia, and that the medication is prescribed by or in consultation with a hematologist.

Drugs / Products Referenced

Drugs / Products referenced (no billing codes provided in policy)mixed

deferasirox (Exjade, Jadenu, generics)	Oral deferasirox formulations: tablets for suspension, tablets, oral granules (Jadenu Sprinkle)
deferiprone (Ferriprox, generics)	Tablets (500 mg, 1000 mg) and oral solution (100 mg/mL)

Clinical Evidence & Guidance

Background: Oral iron chelators deferasirox (Exjade, Jadenu, generics) and deferiprone (Ferriprox, generics) are indicated to treat chronic iron overload due to repeated blood transfusions and certain non‑transfusion‑dependent thalassemias; deferasirox formulations share the same active ingredient across formulations.

Boxed warning / safety considerations for deferiprone: guidelines note concern due to the agent's Boxed Warning for agranulocytosis, and NCCN guidance highlights controversy regarding deferiprone use in MDS because of this boxed warning.

Guideline evidence: Thalassemia International Federation recommends initiating chelation after approximately 10–20 RBC infusions or when serum ferritin > 1,000 mcg/L for transfusion‑dependent patients and supports deferasirox for certain non‑transfusion‑dependent settings (including LIC ≥ 5 mg Fe/g dry weight and ferritin thresholds in guideline text). The NCCN MDS guidance recommends consideration of deferasirox (or deferoxamine) after > 20–30 RBC transfusions aiming for target ferritin < 1,000 mcg/mL.

Policy Revision History

5/1/2024revised

Removed age from Deferasirox indications for Iron Overload, Chronic - Transfusion-Related and Non-Transfusion-Dependent Thalassemia Syndromes. (Annual Revision date 5/1/2024; removal of age requirements from those criteria.)

5/1/2024revised

Removed requirement for Liver Iron Concentration (LIC ≥ 5 mg Fe/g dry weight) from Deferasirox non-transfusion-dependent thalassemia criteria. (Annual Revision date 5/1/2024; LIC threshold removed from policy criteria.)

5/1/2024added

Policy Summary

PayerCigna

PolicyIron Chelators (Oral)

Policy CodePolicy IP0271

Change TypeAnnual revisions (2024, 2025) - criteria & preferred product updates

Effective DateMay 1, 2025

Next Review Date

Key ActionDocument required serum ferritin thresholds and hematology consultation for initiation and follow plan-specific preferred product/prior authorization requirements.

SourceLink

On This Page

Ferriprox (deferiprone) 1000 mg tablets twice daily criteria: Criteria = ONE of the following: 1) Patient has tried generic deferiprone tablets; OR 2) Dose prescribed cannot be attained with deferiprone tablets.

Employer and Individual & Family Plans list this option; may require prior authorization on some lines.

Ferriprox (deferiprone) 500 mg or 1000 mg tablets three times daily criteria: Criteria = Trial of deferiprone 500 mg or 1000 mg tablet (the bioequivalent generic product) AND cannot take due to a formulation difference in the inactive ingredient(s) which would result in a significant allergy or serious adverse reaction.

Employer and Individual & Family Plans; may require prior authorization.

Ferriprox oral solution criteria (Employer and Individual & Family Plans): Criteria = ONE of the following: 1) Patient has tried generic deferiprone tablets; OR 2) Dose prescribed cannot be attained with deferiprone tablets; OR 3) Patient cannot swallow or has difficulty swallowing tablets.

Added option to include inability to swallow or difficulty swallowing tablets per revision.

Billing Rule

Approval duration

Approvals are for 1 year when criteria are met.

Step Therapy

Preferred product / step requirements

Plan-specific requirements typically require trial of the bioequivalent generic product (for example, deferasirox tablet for suspension/tablet/granules or deferiprone tablets) and documentation that the patient cannot take the generic due to a formulation difference in inactive ingredients causing significant allergy or serious adverse reaction; for deferiprone solution, alternatives include documented inability to attain dose with tablets or inability to swallow tablets.

Denial Risk

Not covered if indication not supported

Any other use is considered experimental, investigational, or unproven and is not covered until criteria are updated with published data.

Documentation Required

Samples do not satisfy criteria

Receipt of sample product does not satisfy any criteria requirements for coverage (Individual and Family Plans).

Ferriprox oral solution criteria expanded to include 'Dose prescribed cannot be attained with deferiprone tablet' and 'patient who cannot swallow or have difficulty swallowing tablets' as acceptable options for Employer and Individual & Family Plans. (Added for Employer and Individual & Family Plans. Annual Revision date 5/1/2024.)

5/1/2025revisedLatest

Updated verbiage for 'Patients Currently Receiving an Oral Chelator' approval to 'Approve if the patient is benefiting from therapy, according to the prescriber.' (Annual Revision date 5/1/2025; clarified continuation approval wording.)

5/1/2025revisedLatest

Updated preferred product criteria for Ferriprox 1000 mg (twice daily) and Ferriprox 500 mg/1000 mg (three times daily) formulations; removed some prior product criteria for Individual and Family Plans and updated others. (Annual Revision date 5/1/2025; removed some prior product criteria for Individual and Family Plans and updated others.)